Medicus Pharma (NASDAQ:MDCX) earlier this week announced the submission of a key European regulatory package designed to support the launch of a Phase 2b clinical study of Teverelix in advanced prostate cancer patients with elevated cardiovascular risk.
Speaking with Proactive, chief medical officer Dr Faisal Mehmud said the filing represents an important regulatory milestone for the programme and marks a significant step toward advancing the company's development strategy in an underserved patient population.
Mehmud explained that the planned Phase 2b study is intended to optimize dosing while generating data needed to support the future registration pathway for Teverelix. The company plans to conduct the study primarily in Europe and is targeting initiation during the third quarter, subject to regulatory review.
According to Mehmud, cardiovascular disease remains a major challenge among men receiving androgen deprivation therapy for advanced prostate cancer. He noted that cardiovascular disease is the leading cause of death in many patients within this treatment setting and that roughly one-third of patients have significant underlying cardiovascular disease.
The executive said no hormonal therapy currently carries a specific label focused on patients with elevated cardiovascular risk, creating what he described as a significant unmet medical need. He added that this represents a potentially important commercial and clinical opportunity for Medicus Pharma (NASDAQ:MDCX).
The planned single-arm study will assess whether the selected Teverelix dose can reliably achieve and maintain testosterone suppression. The company also intends to further characterise the treatment's safety profile and evaluate follicle-stimulating hormone (FSH) suppression.
Mehmud stated that complete FSH suppression may be particularly relevant in patients with elevated cardiovascular risk and is expected to be an important area of investigation within the trial.
He highlighted that while existing GnRH antagonists, including Degarelix and Relugolix, have demonstrated encouraging cardiovascular findings, neither was specifically developed or prospectively studied to obtain a cardiovascular risk-focused label. Medicus Pharma's strategy, he said, is to generate the clinical evidence required to support a differentiated positioning for Teverelix.
Among the key catalysts for investors will be European regulatory clearance to begin the study, patient recruitment progress, completion of enrolment, and the generation of clinical data supporting both efficacy and safety objectives. Successful execution of the Phase 2b programme could play a significant role in advancing the company's broader registration strategy.
As Mehmud told Proactive, the submission is "an important regulatory milestone for the Teverelix program" and is intended to support development in a "large and underserved population of prostate cancer patients with elevated cardiovascular risk."